Bayer AG’s (BAYRY.OB) Finerenone, an investigational drug for patients with chronic kidney disease (CKD) and type 2 diabetes is under priority review by the FDA, with a decision expected on July 12.Chronic kidney disease (CKD) is one of the most frequent complications arising from diabetes. It is estimated that 40% of individuals with type 2 diabetes are at risk of developing chronic kidney disease.In a pivotal phase III trial, Finerenone delayed the progression of chronic kidney disease (CKD) in patients with type 2 diabetes and CKD.Finerenone, if approved will have to compete with AstraZeneca’s Farxiga and Johnson & Johnson’s Invokana. BAYRY.OB closed Wednesday’s (Jun.23, 2021) trading at $15.19, down 1.17%.